ReviewThe European respiratory journal2024
Chronic thromboembolic pulmonary disease.
Review in The European respiratory journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07272798 (Cardiac Self-Efficacy in Patients With Chronic Thromboembolic Pulmonary Hypertension), which is not on this map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Cardiac Self-Efficacy in Patients With Chronic Thromboembolic Pulmonary Hypertension
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Placebo Effect in Chronic Thromboembolic Pulmonary Hypertension Trials: A Systematic Review and Meta-Analysis.Medical sciences (Basel, Switzerland) · 2025Pooled it
- Article
- ESR Bridges: chronic thromboembolic pulmonary hypertension: new developments in imaging and treatment-a multidisciplinary view.European radiology · 2026Article
- Pulmonary thromboendarterectomy at leading high-volume centers: International perspectives.JHLT open · 2026Article
- The Evolving Landscape of Pulmonary Hypertension Treatment: From Vasodilation to Disease Modification.Clinical and translational science · 2026Review
- ERS Congress 2025: highlights from the Pulmonary Vascular Diseases Assembly.ERJ open research · 2026Article
- Haemodynamic partial remission as a prognostic target in pulmonary arterial hypertension.ERJ open research · 2026Article
- The Role of Medical Therapy Before and After Balloon Pulmonary Angioplasty: CTEPH AC Registry Across Japan.Pulmonary circulation · 2026Article
- Activin Signaling Inhibitors in Pulmonary Hypertension: A State-of-the-Art Review.Pulmonary circulation · 2026Review
- Outpatient Point-of-Care Cardiopulmonary Exercise Testing in Chronic Thromboembolic Pulmonary Disease: A Single-Center Experience.JACC. Advances · 2026Article
- Observational
- Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension in an Adolescent With a Novel Frameshift Variant in PROS1.Pulmonary circulation · 2026Article
- Imaging in chronic thromboembolic pulmonary hypertension: review of the current literature.Diagnostic and interventional radiology (Ankara, Turkey) · 2026Review
- Temporal Trends in Age Profile and Safety of Balloon Pulmonary Angioplasty for CTEPH.JACC. Asia · 2026Article
- One Health Insights into Pulmonary Hypertension: Bridging Human and Canine Medicine.Veterinary sciences · 2026Review
- Update on pulmonary hypertension.Respiratory research · 2026Review
- Clonal Hematopoiesis (CHIP) in Pulmonary Embolism and CTEPH: Evidence, Mechanisms, and Risk Stratification.International journal of molecular sciences · 2026Review
- Real-World Treatment Patterns and Burden of Chronic Thromboembolic Pulmonary Hypertension Patients across Consultation Settings in the USA.Pulmonary therapy · 2026Article
- Review
- Review
Corrections and comments
- Commented on by
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic thromboembolic pulmonary hypertension is a complication of pulmonary embolism and a treatable cause of pulmonary hypertension. The pathology is a unique combination of mechanical obstruction due to failure of clot resolution, and a variable degree of microvascular disease, that both contribute to pulmonary vascular resistance. Accordingly, multiple treatments have been developed to target the disease components. However, accurate diagnosis is often delayed. Evaluation includes high-quality imaging modalities, necessary for disease confirmation and for appropriate treatment planning. All patients with chronic thromboembolic pulmonary disease, and especially those with pulmonary hypertension, should be referred to expert centres for multidisciplinary team decision on treatment. The first decision remains assessment of operability, and the best improvement in symptoms and survival is achieved by the mechanical therapies, pulmonary endarterectomy and balloon pulmonary angioplasty. With the advances in multimodal therapies, excellent outcomes can be achieved with 3-year survival of >90%.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.